CollPlant’s rhCollagen-based Photocurable Dermal Filler Shows Promise for Facial Lifting and Sculpting and Breast Augmentation/Reconstruction

CollPlant's photocurable dermal filler may enhance cell proliferation and new tissue regeneration for facial lifting and sculpting plus breast augmentation and reconstruction , according to in-vitro and in-vivo results published in Plastic and Reconstructive Surgery.

CollPlant's photocurable dermal filler is composed of rhCollagen and hyaluronic acid and is intended for contour deficiencies corrections. The filler is designed to allow easy injection, followed by sculpting and in-situ hardening by light illumination of the skin.

Following light illumination of the skin, CollPlant's photocurable dermal filler showed improved physical properties compared with standard of care, suggesting enhanced lifting effect and appearance, the study showed. Biological properties assessed in a preclinical animal model found that the photocurable filler enhances cell proliferation and new tissue regeneration compared to standard of care.

"We are very pleased with these promising results of CollPlant's photocurable collagen technology, demonstrating its broad potential in aesthetic medicine applications,” says Yehiel Tal, CollPlant's Chief Executive Officer, in a news release. "Regenerative medicine aims to mimic nature, providing cells with growing environment as similar as possible to the original one. These published results further demonstrate recombinant human collagen's (rhCollagen) ability to serve as the ideal building block in regenerative medicine application." 

At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Later in 2021, CollPlant entered into a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.